VANCOUVER, British Columbia, Feb. 9, 2011 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) today announced results from a Phase II proof-of-concept clinical trial for the olopatadine punctal plug delivery system (O-PPDS).
